摘要
目的:探讨齐拉西酮与利培酮治疗精神分裂症的疗效和安全性。方法:将60例精神分裂症患者随机分为齐拉西酮组和利培酮组,每组30例。疗程8周,采用阳性与阴性症状量表(PANSS)和治疗中出现的症状量表(TESS)评定疗效和不良反应。结果:齐拉西酮组有效率83.3%,显效率70.0%,利培酮组有效率86.7%,显效率73.3%。结论:齐拉西酮治疗精神分裂症疗效较好与利培酮相当,不良反应少。
Objective：To explore the efficacy and safety of ziprasidone in treatment of schizophrenia. Methods：60 patients with schizophreia were randomly assigned two groups ziprasidone group （n = 30） and respenridone group （n = 30） for 8 week. Positive and negative syndrome scale （PANSS） and treatment side effect scale （TESS）were used to evaluate the efficacy and side effects respectively. Results： The response rate and marked response rate was 83.3% andT0.0% in ziprasidone treatment patients,and which was 86.7% and 73.3% in risperidone randomly patients. Conclusions： Ziprasidone has better treatment efficacy and less adverse effects in schizophrenia.
出处
《中国民康医学》
2008年第17期2002-2002,2004,共2页
Medical Journal of Chinese People’s Health
